GRPN

Prezzo Groupon Inc

Closed
GRPN
$0
+$0(0,00%)
Nessun dato

*Data last updated: 2026-04-29 01:35 (UTC+8)

As of 2026-04-29 01:35, Groupon Inc (GRPN) is priced at $0, with a total market cap of $582,22M, a P/E ratio of -8,49, and a dividend yield of 0,00%. Today, the stock price fluctuated between $0 and $0. The current price is 0,00% above the day's low and 0,00% below the day's high, with a trading volume of 1,24M. Over the past 52 weeks, GRPN has traded between $0 to $0, and the current price is 0,00% away from the 52-week high.

GRPN Key Stats

Yesterday's Close$14
Market Cap$582,22M
Volume1,24M
P/E Ratio-8,49
Dividend Yield (TTM)0,00%
Diluted EPS (TTM)2,08
Net Income (FY)-$83,52M
Revenue (FY)$498,42M
Earnings Date2026-05-07
EPS Estimate0,02
Revenue Estimate$117,64M
Shares Outstanding38,91M
Beta (1Y)-0.044

About GRPN

Groupon, Inc., together with its subsidiaries, operates a marketplace that connects consumers to merchants. It operates in two segments, North America and International. The company sells goods or services on behalf of third-party merchants; and first-party goods inventory. It serves customers through its mobile applications and websites. The company was formerly known as ThePoint.com, Inc. and changed its name to Groupon, Inc. in October 2008. Groupon, Inc. was incorporated in 2008 and is headquartered in Chicago, Illinois.
SectorCommunication Services
IndustryInternet Content & Information
CEODusan Senkypl
HeadquartersChicago,IL,US
Official Websitehttps://www.groupon.com
Employees (FY)470,00
Average Revenue (1Y)$1,06M
Net Income per Employee-$177,70K

Groupon Inc (GRPN) FAQ

What's the stock price of Groupon Inc (GRPN) today?

x
Groupon Inc (GRPN) is currently trading at $0, with a 24h change of 0,00%. The 52-week trading range is $0–$0.

What are the 52-week high and low prices for Groupon Inc (GRPN)?

x

What is the price-to-earnings (P/E) ratio of Groupon Inc (GRPN)? What does it indicate?

x

What is the market cap of Groupon Inc (GRPN)?

x

What is the most recent quarterly earnings per share (EPS) for Groupon Inc (GRPN)?

x

Should you buy or sell Groupon Inc (GRPN) now?

x

What factors can affect the stock price of Groupon Inc (GRPN)?

x

How to buy Groupon Inc (GRPN) stock?

x

Risk Warning

The stock market involves a high level of risk and price volatility. The value of your investment may increase or decrease, and you may not recover the full amount invested. Past performance is not a reliable indicator of future results. Before making any investment decisions, you should carefully assess your investment experience, financial situation, investment objectives, and risk tolerance, and conduct your own research. Where appropriate, consult an independent financial adviser.

Disclaimer

The content on this page is provided for informational purposes only and does not constitute investment advice, financial advice, or trading recommendations. Gate shall not be held liable for any loss or damage resulting from such financial decisions. Further, take note that Gate may not be able to provide full service in certain markets and jurisdictions, including but not limited to the United States of America, Canada, Iran, and Cuba. For more information on Restricted Locations, please refer to the User Agreement.

Other Trading Markets

Hot Posts su Groupon Inc (GRPN)

MetaMaskVictim

MetaMaskVictim

2025-12-31 14:26
## Institutional Confidence in Pharmaceutical Turnaround A Prague-based investment fund has made a significant bet on pharmaceutical sector recovery. Pale Fire Capital SE expanded its position in **Teva** (NYSE:TEVA) by purchasing 639,162 additional shares during Q3, pushing its total holding to approximately 1.7 million shares worth $34.13 million as of September 30. This $16.53 million increase in position value suggests deliberate confidence in the company's operational stabilization. ## Why This Timing Matters Teva's journey has been dramatic. The stock once collapsed nearly 90% from its peaks, but recent performance tells a different story. Over the past year, shares have appreciated 41%, outpacing the S&P 500's 15% gain. Yet despite this recovery, the stock still trades roughly 55% below its 2015 highs—creating what value investors characterize as a gap between current valuation and fundamental recovery. ## The Business Case for Recovery **Teva** generates $16.78 billion in annual revenue (TTM) and $713 million in net income, making it a substantial player in the pharmaceutical ecosystem. The company's portfolio spans: - Generic medicines across therapeutic areas - Specialty pharmaceuticals for complex treatments - Biopharmaceutical products for rare and chronic conditions - Global distribution serving North America, Europe, and international markets The operational narrative has shifted materially. Q3 results demonstrated margin expansion and improved cash generation, with net debt declining substantially over recent years. This directly addresses the balance-sheet vulnerability that previously haunted the bear case. ## Portfolio Context: A Recovery-Focused Strategy Within Pale Fire Capital SE's broader holdings (which include positions in gold miners, consumer turnarounds, and distressed global equities valued at $34.13 million for Teva alone), this position reflects a thesis around durable re-rating rather than explosive growth. The fund's top holdings include BTG ($247.58M, 27.1% of AUM), GRPN ($237.73M, 26.1%), and DOLE ($115.42M, 12.7%), indicating a portfolio built around operationally stabilized companies trading below intrinsic value. ## The Investment Thesis: Valuation vs. Fundamentals For long-term investors, the key question is whether Teva's current valuation adequately reflects a repaired pharmaceutical business operating through a full market cycle. At $31.89 per share, the market appears to be pricing in continued uncertainty despite demonstrated operational progress. The gap between past glory and present pricing creates the opportunity—but only if management can maintain cash flow defense and operational discipline moving forward. Pale Fire Capital SE's Q3 accumulation signals institutional belief that this repair story still has room to run.
0
0
0
0
MevHunter

MevHunter

04-07 23:04
Just dug into some old market analysis from back in 2019 about penny stocks worth considering. Interesting to see how these plays panned out over the years. So first up was AK Steel (AKS). The steel industry is actually way more chaotic than people think - supply and demand constantly shifting, making it tough for companies to plan ahead. AKS had basically flatlined for 15 years before that article, with everything that could go wrong actually going wrong at the worst times. The thesis back then was that Trump's trade policies and a strengthening global economy might finally give steel companies some breathing room. Whether that materialized is another story. Then there was PDL BioPharma (PDLI). This one's an interesting case study in how a business model can become obsolete. PDL originally made money by acquiring drug rights and patents, then licensing them out for dividends. But eventually pharma companies figured out they could do this themselves, so PDL lost its competitive edge. The stock had already crashed from over $30 in 2006 down to under $4 by the time that article ran. Classic story of disruption eating into margins. Groupon (GRPN) is probably the most dramatic fall from grace on this list. Went public at $28 in 2011 as this hot market darling, then tanked into penny stock territory within a year. The daily deals model just didn't have the staying power people thought it did. By 2019, analysts were cautiously optimistic that the company had finally figured out a sustainable path forward, expecting EPS growth even if sales dipped. And Zynga (ZNGA) - yeah, the company behind Words With Friends and FarmVille. Took a huge hit when Facebook dropped the exclusivity deal back in 2012, which basically derailed the IPO momentum. What was interesting about the 2019 outlook was that founder Mark Pincus had given up his dual-class voting structure, which some thought could unlock better decision-making and growth. Looking back at penny stocks from that era, it's a good reminder that cheap prices often reflect real problems. But occasionally you do find situations where the market's being too pessimistic about a turnaround. The key is figuring out which is which.
1
0
0
0
ForkLibertarian

ForkLibertarian

04-07 08:52
Economic Releases Scheduled for the Coming Week ----------------------------------------------- ### Tuesday, March 10 * February Existing Home Sales (seasonally adjusted annual rate) — FactSet consensus 3,780K vs. 3,910K in January ### Wednesday, March 11 * February Consumer Price Index report * CPI (month to month) — FactSet consensus 0.2% vs. 0.2% in January * Core CPI (month to month) — FactSet consensus 0.28% vs. 0.30% in January * CPI (year over year) — FactSet consensus 2.4% vs. 2.4% in January * Core CPI (year over year) — FactSet consensus 1.5% vs. 2.5% in January ### Thursday, March 12 * Housing Starts (seasonally adjusted annual rate) — FactSet consensus 1,320K vs. 1,404K in December * Initial Unemployment Insurance Claims report for the week ended March 7 — FactSet consensus 215K vs. 213K for the week ended Feb. 28 ### Friday, March 13 * January Durable Orders (month to month) — FactSet consensus 0.55% vs. -1.4% in December * Q4 GDP (seasonally adjusted annual rate) — FactSet consensus 2.0% vs. 1.4% in Q3 * January Personal Income and Outlays report * Personal Income (month to month) — FactSet consensus 0.4% vs. 0.3% in December * Personal Consumption Expenditure (month to month) — FactSet consensus N/A vs. 0.4% in December * PCE Deflator (year over year) — FactSet consensus 2.8% vs. 2.9% in December * Core PCE Deflator (year over year) — FactSet consensus 2.9% vs. 3.0% in December Company Earnings ---------------- * Tuesday, March 10: Oracle ORCL * Wednesday, March 11: Groupon GRPN * Thursday, March 12: Adobe ADBE
0
0
0
0